Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.

TitleMyeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Publication TypeJournal Article
Year of Publication2017
AuthorsScott, BL, Pasquini, MC, Logan, BR, Wu, J, Devine, SM, Porter, DL, Maziarz, RT, Warlick, ED, Fernandez, HF, Alyea, EP, Hamadani, M, Bashey, A, Giralt, S, Geller, NL, Leifer, E, Le-Rademacher, J, Mendizabal, AM, Horowitz, MM, H Deeg, J, Horwitz, ME
JournalJ Clin Oncol
Volume35
Issue11
Pagination1154-1161
Date Published2017 Apr 10
ISSN1527-7755
KeywordsAdult, Aged, Antineoplastic Combined Chemotherapy Protocols, Busulfan, Cause of Death, Cyclosporine, Disease-Free Survival, Female, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Immunosuppressive Agents, Kaplan-Meier Estimate, Leukemia, Myeloid, Acute, Male, Melphalan, Middle Aged, Myelodysplastic Syndromes, Recurrence, Survival Rate, Transplantation Conditioning, Transplantation, Homologous, Vidarabine, Whole-Body Irradiation, Young Adult
Abstract

Purpose The optimal regimen intensity before allogeneic hematopoietic cell transplantation (HCT) is unknown. We hypothesized that lower treatment-related mortality (TRM) with reduced-intensity conditioning (RIC) would result in improved overall survival (OS) compared with myeloablative conditioning (MAC). To test this hypothesis, we performed a phase III randomized trial comparing MAC with RIC in patients with acute myeloid leukemia or myelodysplastic syndromes. Patients and Methods Patients age 18 to 65 years with HCT comorbidity index ≤ 4 and

DOI10.1200/JCO.2016.70.7091
Alternate JournalJ Clin Oncol
PubMed ID28380315
PubMed Central IDPMC5455603
Grant ListU10 HL069294 / HL / NHLBI NIH HHS / United States
UG1 HL069290 / HL / NHLBI NIH HHS / United States
U10 HL069290 / HL / NHLBI NIH HHS / United States
U24 CA076518 / CA / NCI NIH HHS / United States
UG1 HL069315 / HL / NHLBI NIH HHS / United States
P30 CA008748 / CA / NCI NIH HHS / United States
UG1 HL109137 / HL / NHLBI NIH HHS / United States
U10 HL109322 / HL / NHLBI NIH HHS / United States
U10 HL069315 / HL / NHLBI NIH HHS / United States